Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Identifieur interne : 004280 ( Main/Exploration ); précédent : 004279; suivant : 004281Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Auteurs : Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-11.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Agonist, Animal, Animal model, Animals, Antiparkinson Agents (toxicity), Antiparkinson agent, Benserazide (toxicity), Callithrix, Cannabinoid receptor, Chemotherapy, Corpus Striatum (drug effects), Corpus Striatum (physiopathology), Dose-Response Relationship, Drug, Dronabinol (analogs & derivatives), Dronabinol (pharmacology), Drug Combinations, Drug Therapy, Combination, Dyskinesia, Dyskinesia, Drug-Induced (physiopathology), Female, Globus Pallidus (drug effects), Globus Pallidus (physiopathology), Levodopa, Levodopa (toxicity), MPTP, Male, Monkey, Motor Skills (drug effects), Nabilone, Parkinson disease, Parkinson's disease, Parkinsonian Disorders (physiopathology), Receptors, Cannabinoid, Receptors, Drug (drug effects), Receptors, Drug (physiology), Treatment, cannabinoid, dyskinesia, gamma-Aminobutyric Acid (metabolism), nabilone.
- MESH :
- chemical , analogs & derivatives : Dronabinol.
- chemical , drug effects : Receptors, Drug.
- chemical , metabolism : gamma-Aminobutyric Acid.
- chemical , pharmacology : Dronabinol.
- chemical , physiology : Receptors, Drug.
- chemical , toxicity : Antiparkinson Agents, Benserazide, Levodopa.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Drug Combinations, Receptors, Cannabinoid.
- drug effects : Corpus Striatum, Globus Pallidus, Motor Skills.
- physiopathology : Corpus Striatum, Dyskinesia, Drug-Induced, Globus Pallidus, Parkinsonian Disorders.
- Animals, Callithrix, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Male.
Abstract
Long‐term treatment with levodopa in Parkinson's disease results in the development of motor fluctuations, including reduced duration of antiparkinsonian action and involuntary movements, i.e., levodopa‐induced dyskinesia. Cannabinoid receptors are concentrated in the basal ganglia, and stimulation of cannabinoid receptors can increase γ‐aminobutyric acid transmission in the lateral segment of globus pallidus and reduce glutamate release in the striatum. We thus tested the hypothesis that the cannabinoid receptor agonist nabilone (0.01, 0.03, and 0.10 mg/kg) would alleviate levodopa‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine hydrochloride (MPTP) ‐lesioned marmoset model of Parkinson's disease. Coadministration of nabilone (0.1 mg/kg) with levodopa was associated with significantly less total dyskinesia (dyskinesia score, 12; range, 6–17; primate dyskinesia rating scale) than levodopa alone (22; range, 14–23; P < 0.05). This effect was more marked during the onset period (0–20 minutes post levodopa). There was no reduction in the antiparkinsonian action of levodopa. Furthermore, the intermediate dose of nabilone used (0.03 mg/kg) increased the duration of antiparkinsonian action of levodopa by 76%. Thus, cannabinoid receptor agonists may be useful in the treatment of motor complications in Parkinson's disease. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10289
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000838
- to stream Istex, to step Curation: 000838
- to stream Istex, to step Checkpoint: 002B71
- to stream PubMed, to step Corpus: 003924
- to stream PubMed, to step Curation: 003924
- to stream PubMed, to step Checkpoint: 003926
- to stream Ncbi, to step Merge: 000927
- to stream Ncbi, to step Curation: 000927
- to stream Ncbi, to step Checkpoint: 000927
- to stream Main, to step Merge: 006285
- to stream PascalFrancis, to step Corpus: 002598
- to stream PascalFrancis, to step Curation: 000723
- to stream PascalFrancis, to step Checkpoint: 002601
- to stream Main, to step Merge: 006640
- to stream Main, to step Curation: 004280
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name></author><author><name sortKey="Henry, Brian" sort="Henry, Brian" uniqKey="Henry B" first="Brian" last="Henry">Brian Henry</name></author><author><name sortKey="Hill, Michael" sort="Hill, Michael" uniqKey="Hill M" first="Michael" last="Hill">Michael Hill</name></author><author><name sortKey="Crossman, Alan" sort="Crossman, Alan" uniqKey="Crossman A" first="Alan" last="Crossman">Alan Crossman</name></author><author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0D72950B7DD74740B4CC2AF207D9BF963CD0F918</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10289</idno><idno type="url">https://api.istex.fr/document/0D72950B7DD74740B4CC2AF207D9BF963CD0F918/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000838</idno><idno type="wicri:Area/Istex/Curation">000838</idno><idno type="wicri:Area/Istex/Checkpoint">002B71</idno><idno type="wicri:doubleKey">0885-3185:2002:Fox S:stimulation:of:cannabinoid</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:12465055</idno><idno type="wicri:Area/PubMed/Corpus">003924</idno><idno type="wicri:Area/PubMed/Curation">003924</idno><idno type="wicri:Area/PubMed/Checkpoint">003926</idno><idno type="wicri:Area/Ncbi/Merge">000927</idno><idno type="wicri:Area/Ncbi/Curation">000927</idno><idno type="wicri:Area/Ncbi/Checkpoint">000927</idno><idno type="wicri:doubleKey">0885-3185:2002:Fox S:stimulation:of:cannabinoid</idno><idno type="wicri:Area/Main/Merge">006285</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:03-0038697</idno><idno type="wicri:Area/PascalFrancis/Corpus">002598</idno><idno type="wicri:Area/PascalFrancis/Curation">000723</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002601</idno><idno type="wicri:doubleKey">0885-3185:2002:Fox S:stimulation:of:cannabinoid</idno><idno type="wicri:Area/Main/Merge">006640</idno><idno type="wicri:Area/Main/Curation">004280</idno><idno type="wicri:Area/Main/Exploration">004280</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Oxford Road, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Current Address: Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="Henry, Brian" sort="Henry, Brian" uniqKey="Henry B" first="Brian" last="Henry">Brian Henry</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Oxford Road, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Current Address: Organon Laboratories Limited, Lanarkshire, Scotland, ML1 5SH</wicri:regionArea><wicri:noRegion>ML1 5SH</wicri:noRegion></affiliation></author><author><name sortKey="Hill, Michael" sort="Hill, Michael" uniqKey="Hill M" first="Michael" last="Hill">Michael Hill</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd., Manchester Science Park, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Crossman, Alan" sort="Crossman, Alan" uniqKey="Crossman A" first="Alan" last="Crossman">Alan Crossman</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd., Manchester Science Park, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd., Manchester Science Park, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-11">2002-11</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1180">1180</biblScope><biblScope unit="page" to="1187">1187</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0D72950B7DD74740B4CC2AF207D9BF963CD0F918</idno><idno type="DOI">10.1002/mds.10289</idno><idno type="ArticleID">MDS10289</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Agonist</term><term>Animal</term><term>Animal model</term><term>Animals</term><term>Antiparkinson Agents (toxicity)</term><term>Antiparkinson agent</term><term>Benserazide (toxicity)</term><term>Callithrix</term><term>Cannabinoid receptor</term><term>Chemotherapy</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (physiopathology)</term><term>Dose-Response Relationship, Drug</term><term>Dronabinol (analogs & derivatives)</term><term>Dronabinol (pharmacology)</term><term>Drug Combinations</term><term>Drug Therapy, Combination</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Female</term><term>Globus Pallidus (drug effects)</term><term>Globus Pallidus (physiopathology)</term><term>Levodopa</term><term>Levodopa (toxicity)</term><term>MPTP</term><term>Male</term><term>Monkey</term><term>Motor Skills (drug effects)</term><term>Nabilone</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Parkinsonian Disorders (physiopathology)</term><term>Receptors, Cannabinoid</term><term>Receptors, Drug (drug effects)</term><term>Receptors, Drug (physiology)</term><term>Treatment</term><term>cannabinoid</term><term>dyskinesia</term><term>gamma-Aminobutyric Acid (metabolism)</term><term>nabilone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dronabinol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Drug</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>gamma-Aminobutyric Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Dronabinol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Drug</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Drug Combinations</term><term>Receptors, Cannabinoid</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Globus Pallidus</term><term>Motor Skills</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term><term>Dyskinesia, Drug-Induced</term><term>Globus Pallidus</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Callithrix</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Female</term><term>Male</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term><term>Animal</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Dyskinésie</term><term>Lévodopa</term><term>Modèle animal</term><term>Nabilone</term><term>Parkinson maladie</term><term>Récepteur cannabinoïde</term><term>Singe</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Long‐term treatment with levodopa in Parkinson's disease results in the development of motor fluctuations, including reduced duration of antiparkinsonian action and involuntary movements, i.e., levodopa‐induced dyskinesia. Cannabinoid receptors are concentrated in the basal ganglia, and stimulation of cannabinoid receptors can increase γ‐aminobutyric acid transmission in the lateral segment of globus pallidus and reduce glutamate release in the striatum. We thus tested the hypothesis that the cannabinoid receptor agonist nabilone (0.01, 0.03, and 0.10 mg/kg) would alleviate levodopa‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine hydrochloride (MPTP) ‐lesioned marmoset model of Parkinson's disease. Coadministration of nabilone (0.1 mg/kg) with levodopa was associated with significantly less total dyskinesia (dyskinesia score, 12; range, 6–17; primate dyskinesia rating scale) than levodopa alone (22; range, 14–23; P < 0.05). This effect was more marked during the onset period (0–20 minutes post levodopa). There was no reduction in the antiparkinsonian action of levodopa. Furthermore, the intermediate dose of nabilone used (0.03 mg/kg) increased the duration of antiparkinsonian action of levodopa by 76%. Thus, cannabinoid receptor agonists may be useful in the treatment of motor complications in Parkinson's disease. © 2002 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Manchester</li></region><settlement><li>Manchester</li></settlement><orgName><li>Université de Manchester</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name></region><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name><name sortKey="Crossman, Alan" sort="Crossman, Alan" uniqKey="Crossman A" first="Alan" last="Crossman">Alan Crossman</name><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><name sortKey="Henry, Brian" sort="Henry, Brian" uniqKey="Henry B" first="Brian" last="Henry">Brian Henry</name><name sortKey="Henry, Brian" sort="Henry, Brian" uniqKey="Henry B" first="Brian" last="Henry">Brian Henry</name><name sortKey="Hill, Michael" sort="Hill, Michael" uniqKey="Hill M" first="Michael" last="Hill">Michael Hill</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004280 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004280 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0D72950B7DD74740B4CC2AF207D9BF963CD0F918
|texte= Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |